Caravan Biologix, Inc. Collaborates with MDimune on Cell-Derived NanoVesicles for Cancer
15.9.2022 17:00:00 EEST | Business Wire | Press release
Caravan Biologix, Inc., a developer of novel cell-derived vesicle (CDV) therapeutics targeting specific cancers and gene therapy-related diseases, today announced that it has entered into an agreement with Seoul-based MDimune Inc. to apply their nanovesicle technology to enhance the effects of chimeric antigen receptor-expressing natural killer (CAR-NK) cells on various solid tumor cancers. Research findings should provide important insights as Caravan continues to advance the development of its proprietary Mini-CAR™ platform for stand-alone therapeutics and whole-cell CAR co-therapies.
“We are pleased to establish this collaboration with MDimune, a developer of bio-extrusion and delivery,” stated Tom Malcolm, Ph.D., CSO and Founder of Caravan Biologix. “Findings from this collaboration will support our mini- CAR-NK CDV program, which focuses on treating primary liver carcinomas and other human diseases.”
Seung Wook Oh, Ph.D., Chief Scientific Officer of MDimune added, “We are thrilled to launch this collaboration with Caravan Biologix. By joining the advanced mini-CAR-NK technology of Caravan and the enormous therapeutic potential of our vesicle technology, we hope to be able to demonstrate that our BioDrone® platform can significantly escalate the therapeutic promise of current CAR-T/NK-based therapies.”
“The signing of this agreement with Caravan Biologix is another important corporate milestone for MDimune. I am very pleased that our highly innovative and detail-oriented analytical approach to produce the highest quality of cell-derived vesicles at low cost has convinced Caravan Biologix to work with us on such an important endeavor to effectively treat patients with solid tumor cancers. It is clear that new solutions are needed to properly address the complexities associated with traditional whole cell CAR therapeutics,” stated Dr. Oh.
About MDimune Inc.
Founded in 2015, MDimune is dedicated to the development of a next-generation drug delivery platform known as BioDrone®. The company aims to provide a new and flexible modality to generate innovative therapeutics that can address the current challenges of cell & gene therapies. Based on cell-derived vesicles (CDVs) obtained from its proprietary extrusion technology, this novel class of drug carriers will enable highly effective drug delivery to various lesions and allow for treatment with minimum side effects and maximum efficacy. The BioDrone® platform technology is patented in the US, Europe, China, Japan, and Korea. BioDrone® Therapeutics Inc. was founded in 2019 in Seattle, WA to facilitate the global business development of BioDrone® platform technology.
About Caravan Biologix, Inc.
Caravan Biologix is a biotechnology company focused on creating novel therapeutic benefits to broad patient populations by addressing the limitations of whole cell chimeric receptor therapeutics. Caravan’s intellectual property protected technology enables it to develop a wide range of delivery and treatment options from gene editors to small molecules. Our allogeneic iPSC-derived mini-CAR™ and mini-VAN™ platforms, that are based on Cell-Derived Vesicles (CDVs), can be rapidly designed, engineered, and manufactured to build our internal pipeline as well as therapeutics for indications of interest to strategic partners. Caravan’s medicines are expected to show superior safety profiles including lower risk for cytokine release syndrome and other adverse immune reactions. Caravan’s approach will significantly reduce the complexity of manufacturing cell-based therapies, enhance blood-brain barrier penetration properties, and improve the targeted delivery of small molecules and other biologics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005157/en/
Contact information
For further information:
Caravan Biologix, Inc.:
Jeff Riley
CEO
+1.917.510.3773
jeff@caravanbio.com
MDimune Inc.
Seung Wook Oh, Ph.D.:
CSO
+82-2-2655-2636
swoh@mdimune.com; Info@biodroneus.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Xsolla SDK Now Available for Game Developers Globally3.3.2026 16:48:00 EET | Press release
Xsolla, a global video game commerce company that has helped developers launch, grow, and monetize their games, today announced the availability of Xsolla SDK, a unified, cross-platform software development kit that consolidates the company's PC, mobile, and web monetization tools into a single download. Launching at GDC Festival of Games 2026, the Xsolla SDK introduces built-in Payments, Login, Catalog, and Offerwall integration for developers, enabling them to configure their pricing and inventory once and deploy across every supported platform with no reconfiguration required. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303075966/en/ Graphic: Xsolla Xsolla is building all the things to help developers monetize cross-platform with the industry’s best-in-class, battle-tested technical foundation built specifically for games. The Xsolla SDK is powered by two decades of building payment and monetization tools exclusivel
Andersen Consulting Broadens Platform with Reach Consulting3.3.2026 16:30:00 EET | Press release
Andersen Consulting expands its platform in the Middle East through a Collaboration Agreement with Reach Consulting, a digital transformation and advisory firm headquartered in the UAE. Reach Consulting supports organizations in driving growth, managing risk, and navigating complex change through a comprehensive suite of services, including digital transformation, strategy, internal audit, and M&A advisory. With a presence across the UAE, Saudi Arabia, Oman, Qatar, and Jordan, the firm serves public and private sector clients through tailored delivery, cross-functional expertise, and deep local insight. Reach Consulting combines scale with agility to advance operational performance and workforce innovation. “Transformation works best when local insight, cross-functional expertise, and practical execution come together,” said Suhail Shaker, managing director of Reach Consulting. “By collaborating with Andersen Consulting, we combine our regional presence with Andersen’s global platform,
ZAPI GROUP to Showcase New Electrification Solutions at ConExpo/AGG 20263.3.2026 16:03:00 EET | Press release
ZAPI GROUP, a global leader in electrification, will demonstrate new solution capabilities within industrial vehicle electrification at ConExpo/AGG, taking place (March 3-7) in Las Vegas. As electrified construction equipment evolves to include larger, more demanding applications, the group has developed new higher-powered on-board DC/DC converters, inverters, electrical motors, and battery chargers to support those performance requirements, while combining additional utility functions within a compact form-factor. Featured solutions include: For motive power applications, a third-generation high-voltage inverter (ACH3) with customizable control software for enhanced performance, and a permanent magnet, electrical motor solution (IMI), with an integrated, liquid-cooled power-electronic inverter. On the battery-charging front, there will be new high-voltage, high-powered 7.2 kW and 22 kW liquid-cooled on-board solutions designed for 100, 400 or 800V lithium-ion battery packs. The 7.2 kW
Carta Launches CRM with Acquisition of ListAlpha3.3.2026 16:01:00 EET | Press release
Carta, the world’s first fully interconnected system for private capital, today announced it has acquired ListAlpha, the AI-powered CRM and relationship intelligence platform. The acquisition marks the launch of Carta CRM, a major expansion of the Carta ERP that further unifies front-to-back office workflows for the private markets. Private equity and venture capital firms have long operated in a fragmented way, keeping relationship context in siloed CRMs while fund performance data remains trapped in back-office ledgers. This information silo quietly erodes clarity for deal teams and GPs, slowing down teams and decreasing capital velocity. By integrating ListAlpha’s specialized CRM directly into the Carta ecosystem, firms can unify front-office intelligence with back-office execution on a single platform. Effectively, Carta now provides the industry’s first comprehensive ERP for private capital, managing the entire investment lifecycle—seamlessly linking workflows from initial investo
Flexitech Chooses Rimini Street to Extend the Life of its SAP ECC, Accelerate Compliance and Fund Innovation3.3.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™, and the leading third-party support provider for Oracle, SAP and VMware software, today announced Flexitech, a French manufacturer of brake and cooling hose solutions for the global automotive industry, has selected Rimini Support™ for SAP to strengthen security, accelerate compliance readiness and free budget for innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303263951/en/ Flexitech Chooses Rimini Street to Extend the Life of its SAP ECC, Accelerate Compliance and Fund Innovation Rimini Support™ Enables Stability, Compliance and Strategic Reinvestment Flexitech relies on a stable SAP ECC 6 environment to support its worldwide operations across Europe, Asia, North America and South America. As SAP maintenance fees continued to rise and the ROI for a forced migration to S/4HANA remained unclear, Flexitech sought an alternative
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom